MOLOGEN strengthens basis for positive business development with non-recurring expenditure. Positive prognosis for the remaining year

In the second quarter of 2005, MOLOGEN AG (ISIN DE0006637200) has strengthened its basis for a positive operative development through non-recurring expenditures for an expansion of its dSLIM business segment and a better overall capitalization.

The low business volume of 0.3 million Euro in the second quarter was anticipated, as first revenues from the cell- and gene-therapy centers aren't expected before the second half of the year. In the second quarter of 2004, the volume was 1.1 million Euro. A crucial factor for the -1.3 million Euro EBIT is the fact that MOLOGEN significantly expanded its promising dSLIM sector in this quarter. MOLOGEN considers dSLIM-based medication to be a segment with very high potential. Furthermore, costs for the successful capital increase have been booked in the second quarter of 2005. EBIT in the second quarter of 2004 was -0.4 million Euro.

The operational cash flow in the second quarter 2005 was -0.9 million Euro, due to increased activities in research and development. The operational cash flow in the second quarter 2004 was -0.5 million Euro. The inventory of financial resources went up from 0.9 million Euro on March 31, 2005 to 2.1 million Euro on June 30, 2005.

The accumulated volume in the first half of this year was 0.4 million Euro with an EBIT of -2.0 million. In the first half of the previous year, the volume was 1.1 million Euro, the EBIT -1.2 million Euro.

MOLOGEN's operative milestones in the first half of 2005 have been the participation in the joint venture INMOG as well as the progress made in research and development. In the third quarter of 2005, INMOG will push the marketing of cell- and gene-therapy centers. In the research segment, significant progress has been made in the development of a MIDGE-based vaccine against leishmaniasis in humans. In the area of dSLIM, preparatory projects for clinical studies and the development of dSLIM-based medication against cancer of the liver, the colon, and the kidneys also progressed well.

Based on existing contracts and further revenues, MOLOGEN's prospect for the second half of 2005 includes a clearly positive cash flow and positive EBIT.

Download Half-year Report 2005

Press Releases

About MOLOGEN

MOLOGEN uses its proprietary DNA technologies to create and develop treatments for high-unmet-need illnesses. The main focuses are the unique and patented MIDGE and dSLIM technologies. Based on these platforms, MOLOGEN is developing DNA-based vaccines and therapeutics to prevent or cure a wide range of diseases.

Going public in 1998, MOLOGEN was one of the first German biotechnology companies to be floated on the stock exchange. The MOLOGEN shares are traded on the Geregelter Markt in Frankfurt.

Disclaimer concerning prognoses

Certain statements in this communication contain formulations or terms referring to the future or future developments, as well as negations of such formulations or terms, or similar terminology. These are described as forward-looking statements. In addition, all information in this communication regarding planned or future results of business segments, financial classification numbers, developments of the financial situation, or other financial or statistical data contains such forward-looking statements. The company cautions prospective investors not to rely on such forward-looking statements as certain prognoses of actual future events and developments. The company is neither responsible nor liable for these forward-looking statements. It is not responsible for updating such information, which only represents the state of affairs on the day of publication.

back to the overview